Background: Mechanical circulatory support (MCS) of a failing Fontan circulation remains challenging. We hypothesized that MCS can be provided by converting the Fontan circulation into a mechanically assisted single ventricle parallel circulation (MASVC). Methods: A porcine model of functionally univentricular circulation was created under cardiopulmonary bypass (CPB) by performing an atrial septectomy, tricuspid valvectomy, and interrupting antegrade pulmonary blood flow. A centrifugal flow pump was placed with inflow from the common atrium. Eight millimeter Dacron grafts anastomosed to the ascending aorta and main pulmonary artery supplied systemic (Qs) and pulmonary (Qp) blood flow. Ultrasonic flow probes were used to measure Qs and Qp after weaning from CPB. The Qp/Qs ratio was regulated using an adjustable clamp. Hemodynamic and laboratory data were recorded. Results: All four animals were successfully weaned from CPB onto the MASVC for a duration of two hours. Mechanically assisted single ventricle parallel circulation achieved satisfactory hemodynamics. As anticipated, the arterial oxygen saturation and partial pressure of oxygen in arterial blood were lower in the MASVC compared to baseline biventricular circulation. At the conclusion of the study, there was a trend towards a decrease in the mixed venous saturation with increasing oxygen extraction compared to the baseline. Serum lactate levels increased after weaning from CPB and did not return to baseline after two hours of support. Conclusion: Mechanically assisted single ventricle parallel circulation can be established in a single ventricle animal model. This strategy could potentially provide MCS of a single ventricle circulation. Studies with longer duration of support are required to assess adequacy of support and long-term sustainability.
Introduction
The Fontan operation 1 remains the only treatment option for patients with single ventricle heart defects. Currently in the United States, over 800 Fontan procedures are done each year. 2 The Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database recorded 3,429 patients who have undergone a Fontan operation between January 2012 and December 2015. 2 Although the Fontan operation provides excellent long-term palliation and survival, it eventually fails. 3 Patients with Fontan failure due to increased pulmonary vascular resistance (PVR) are a difficult subset to manage with currently no effective medical or surgical treatment options available. Although the results of orthotopic heart transplant in patients with a failing Fontan circulation are improving, [4] [5] [6] limited mechanical circulatory support (MCS) options are available to bridge these patients to a transplant. A cavopulmonary assist device continues to be an elusive goal. The innovative use of currently available technology and new ideas are needed to deal with the growing problem of failing Fontan circulation. We hypothesized that MCS of a failing Fontan circulation can be provided by converting the Fontan circulation into a shunted single ventricle type of mixed parallel circulation and mechanically supporting the systemic ventricle. To accomplish this, we propose conversion of the Fontan circulation into a mechanically assisted single ventricle circulation (MASVC; Figure 1 ). The feasibility of establishing an MASVC was evaluated in a pilot study using a porcine single ventricle animal model.
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Materials and Methods
All animals received humane care in accordance with the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals. Animal protocols were approved by the University of Michigan, Institutional Animal Care and Use Committee.
Four healthy swine (50 + 10 kg) were induced and maintained under anesthesia per our established laboratory protocols. 7 Animals were intubated with 7.5 mm endotracheal tubes (Telefelx Medical, Inc, Research Triangle Park, North Carolina) and kept on general inhaled anesthesia with 1% to 3% isoflurane (Priamal Enterprises Ltd, Kohir Mandal, Andhra Pradesh, India). Five lead electrocardiogram pads were placed for cardiac monitoring. Volume-controlled mechanical ventilation (Narkomed 2B-North American Drager, Telford, Pennsylvania) was used throughout the experiment. An arterial line was placed in the left femoral artery, and a central venous line was placed in the right internal jugular vein. The pulmonary artery pressure was recorded via direct needle puncture of the main pulmonary artery (MPA). After median sternotomy and before initiating cardiopulmonary bypass (CPB), the baseline hemodynamic and laboratory data were recorded. The baseline cardiac output was measured using a 15-to 20-mm perivascular ultrasonic flow probe (Transonic System, Inc, Ithaca New York) placed over the ascending aorta.
After systemic heparinization, normothermic CPB was established using proximal ascending aortic and bicaval venous cannulation and the following CPB components: a 3.5 L Capiox Advance FX15 hard-shell venous reservoir (Sarns, Terumo, Inc, Somerset, New Jersey), a multi-flow roller pump (Sarns, Terumo, Inc), a Capiox Advance FX15 hollow-fiber oxygenator with integrated arterial filter (Sarns, Terumo, Inc), and a heat exchanger (Sarns, 3M, Inc, Minneapolis, Minnesota), all connected by Tygon 3/8 inch inner diameter polyvinyl chloride tubing (Saint-Grobain Corporation, Malvern, Pennsylvania). The entire system was primed with 1 L of lactated Ringer's solution (Baxter Healthcare Corporation, Deerfield, Illinois), 50 mEq of calcium bicarbonate (Hospira, Inc, LakeForest, Illinois), and 10,000 units of heparin (Sagent Pharmaceuticals, Inc, Schaumberg, Illinois), which was then recirculated within the extracorporeal circuit to 39 C + 1 C.
Creation of Functionally Univentricular Circulation Model
The swine model of functionally univentricular circulation ( Figure 2 ) was created, while the beating heart was supported on cardiopulmonary bypass. Atrial septectomy and tricuspid valvectomy were performed, and antegrade pulmonary blood flow was interrupted by snaring the proximal MPA. Eight millimeter Dacron grafts were anastomosed to the distal MPA and ascending aorta. A Sarns Delphin centrifugal pump (Terumo Cardiovascular, Ann Arbor, Michigan) was used as a ventricular assist device (VAD). The pump was operated at 1250 to 1500 rpms. A 28F venous cannula (Terumo Cardiovascular) was placed via the left atrial appendage and connected to the VAD inflow. The outflow from the VAD was split using a "Y" connector into an aortic outflow and a pulmonary outflow which were then connected to the respective Dacron grafts. Pulmonary (Qp) and aortic flow (Qs) were measured using extracorporeal ultrasonic flow probes (Transonic Systems, Ithaca, New York) placed over the aortic and pulmonary outflow. The Qp was regulated using an adjustable clamp placed over the pulmonary outflow graft. The VAD flow was initiated and the animal was weaned off CPB. The superior vena cava (SVC) and inferior vena cava (IVC) cannulas were removed and MASVC was established. The aortic cannula was retained to transfuse the autologous blood remaining in the CPB circuit. The hematocrit (HCT) was maintained close to baseline levels by limiting crystalloid transfusion. Donor blood transfusion was not utilized to increase the HCT. After a mean arterial pressure (MAP) of at least 50 mm Hg was achieved, the goal was to regulate the pulmonary blood flow to a Qp/Qs ratio of 1:1 for the initial one hour and 1.5:1 during the last one hour of the study. A constant Qp/Qs was maintained for a minimum of 20 minutes before hemodynamic and laboratory data were recorded. The study animals were maintained in the MASVC for two hours, after which they were euthanized.
Statistical Analysis
Continuous data are reported as mean (standard deviation). Paired t tests were used to compare the MASVC data obtained on a Qp/Qs ration of 1:1 and 1.5:1 with the baseline data. A P value less than .05 was considered statistically significant.
Results
The hemodynamic and laboratory data at baseline and in the MASVC are summarized in Table 1 The HCT in the MASVC was maintained close to the baseline HCT (27.2% + 3.6%). As anticipated, the arterial saturation and partial pressure of oxygen in arterial blood on MASVC was lower compared to the baseline biventricular circulation. With the Qp/Qs of 1:1, the mean arterial oxygen saturation (SpO 2 ) was 77.3% + 11.1%; with Qp/Qs of 1:1.5, the mean SpO 2 was 80% + 13.1%. The mixed venous oxygen saturation (MVO 2 ) in the MASVC was 54.3% + 4.6% (Qp/Qs of 1:1) and 50% + 8.5% (Qp/Qs of 1.5:1). An increase in serum lactate was observed immediately after weaning from CPB ( Figure 3 ), but after two hours of MASVC the lactate levels decreased in animals 1, 3, and 4 ( Figure 3 ). Animal 2 had elevated lactate at baseline which peaked to a maximum of 7 mmol/L and remained elevated at the end of two hours of MASVC. At the conclusion of the study, mean serum lactate level remained significantly elevated compared to the baseline.
Discussion
The Fontan circulation is characterized by systemic venous hypertension and low cardiac output. Correction of these hemodynamic abnormalities would require systemic venous decompression along with augmentation of cardiac output. With the exception of orthotopic heart transplantation, no other currently available medical or surgical treatment modality can achieve both objectives.
A Fontan circulation can fail due to systemic ventricular dysfunction, increased PVR, or a combination of both. [8] [9] [10] Isolated systolic ventricular dysfunction can be managed by mechanically supporting the systemic ventricle.
9,10 Most Fontan survivors have preserved systolic ventricular function with a high incidence of diastolic dysfunction. [11] [12] [13] Systemic VAD therapy in patients with preserved systolic function and diastolic dysfunction may provide little benefit and could be associated with increased risk of ventricular collapse due to the small size of the ventricular cavity. 10 Management of Fontan failure due to increased PVR is challenging, with very few medical or surgical treatment options available. 10, [14] [15] [16] Strategies for mechanical support of the failing Fontan circulation have mainly focused on placing a right heart/cavopulmonary assist device to push blood across pulmonary circulation. 17, 18 Although innovative concepts and ideas for a cavopulmonary assist device have been described, 19 no device is available for clinical application. The absence of a reliable Fontan animal model makes testing of cavopulmonary assist devices difficult. We used a single ventricle animal model, which was simple and easy to create. For clinical application of MASVC, we propose using a standard commercially available continuous flow VAD, which should significantly reduce the time required to test and implement this concept into clinical practice.
Attempts at placing a subpulmonary mechanical pump have not been very successful and require extensive modifications of the cavopulmonary circuit. 20 Commercially available left VADs (LVADs) are designed for systemic pressure and are not ideally suited to support pulmonary circulation due to their pressure flow characteristics. 21 A right heart assist device must provide high flow at a low pressure and would still be limited by the function of the systemic ventricle. 21 Since the Fontan circulation frequently fails due to a combination of increased PVR and ventricular dysfunction, 22 the most effective strategy for supporting a Fontan circulation would be to provide mechanical support to both the systemic and pulmonary circulation. 23 Current options for providing biventricular MCS are limited, with the Syncardia total artificial heart (TAH; SynCardia Systems, Inc, Tucson, Arizona) being the only commercially available device. Placement of a TAH in a patient with hypoplastic left heart syndrome is challenging due to the absence of a right atrial cuff. 24 Conversion into a bidirectional Glenn/hemi-Fontan circulation along with mechanical support of the systemic ventricle has been suggested as one of the treatment strategies for managing a failing Fontan circulation. 23, 25 This approach may not be very effective in older patients as the venous return from the IVC will lead to significant arterial desaturation. We propose complete takedown of the Fontan circulation and conversion into a mechanically assisted shunted single ventricle type of mixed circulation. The takedown of the Fontan circulation will ensure complete decompression of the venous system, and the VAD will support the systemic and pulmonary circulation. Although a shunt-based single ventricle single circulation is inherently unstable, we hypothesize that an MASVC will be hemodynamically stable as both the systemic and pulmonary circulations are decompressed and mechanically supported by the VAD.
In a parallel circulation, balancing the pulmonary and systemic blood flow to achieve a Qp/Qs ratio of 1:1 is challenging and may not always be possible. Previous attempts at supporting a shunted single ventricle circulation using pneumatic pumps such as Berlin Heart EXCOR have not been very successful due to the high-flow requirement of a parallel circulation. 26 The success of an MASVC would largely depend on the ability of the VAD to provide adequate flow to support both the systemic and pulmonary circulation, with the latter being more prone to overcirculation relative to the former. In an adult patient with a continuous flow LVAD, the VAD typically provides about 4 to 5 L/min 27, 28 of flow. The native left ventricle has been shown to contribute 0 to 0.5 L/min at rest and 2 to 4 L/min of additional cardiac output at peak exercise. 28 Currently available continuous flow VADs can provide flows of up to 10 L/min. Most patients with a failing Fontan have preserved systolic ventricular function and the native ventricle should be able to generate additional cardiac output to supplement and sustain the high-flow requirement of an MASVC. In an average-sized adult, a current generation continuous flow pump-based MASVC could potentially generate up to 12 to 14 L/min of cardiac output. In biventricular MCS, it is recommended that the right VAD flow should be less than the LVAD flow to prevent left atrial hypertension and pulmonary venous congestion. In an MASVC, the VAD inflow in the ventricular apex effectively decompresses the common atrium, significantly reducing the risk of common atrial hypertension and pulmonary venous congestion even if the Qp/Qs ratio is more than 1:1. Due to this unique configuration, the MASVC should be able to provide hemodynamic stability over a wide range of Qp/Qs. In this study, increasing the Qp/Qs ratio to 1.5:1 did not lead to a significant increase in the pulmonary artery pressure. Although the risk of pulmonary venous congestion is low in this configuration, development of pulmonary hypertension and pulmonary vascular disease could be a potential complication if excessive Qp is provided. As in the case of a left-to-right shunt, if the Qp/Qs ratio in the MASVC is maintained below a ratio of 1:2, the risk of causing pulmonary vascular obstructive disease should be minimized.
The optimal Qp/Qs ratio required to safely maintain an MASVC needs to be determined. Pulmonary vascular resistance is likely to change over time in acute versus chronic settings. In this study, the pulmonary blood flow (Qp) was regulated using an adjustable clamp. Some ability to adjust Qp/Qs within a safe range must be available in this type of circuit. The Qp could be regulated by the size of the pulmonary outflow graft or by using an adjustable band over the pulmonary outflow graft to control pulmonary blood flow. Further study is required to determine the effect of pulmonary outflow graft size on the Qp/Qs ratio in an MASVC. Future in vitro and computational fluid dynamic analysis studies could provide additional data about optimal sizing of the pulmonary outflow graft. In a neonate with shunted single ventricle, determining the diameter of the shunt is critical to prevent pulmonary overcirculation and hemodynamic instability. Since the circulation in an MASVC is well supported by the VAD, determining the size of the pulmonary outflow graft may not be as critical as in a neonate undergoing Norwood stage I palliation. Although excessive Qp needs to be avoided, some degree of pulmonary overcirculation should be well tolerated in an MASVC.
The potential drawback of conversion into an MASVC is the creation of a mixed circulation causing arterial desaturation and increasing the risk of systemic arterial embolization. By relieving systemic venous congestion and augmenting cardiac output, an MASVC should be able to offset the potential adverse effects of mild systemic arterial desaturation. Fontan survivors with a patent fenestration are not fully saturated at baseline, most patients have a resting arterial saturation of 85% to 89%. 29, 30 A patient with a failing Fontan circulation who has a patent fenestration and systemic-to-pulmonary venous collaterals will experience significant arterial desaturation. Clinically a saturation of about 85% is usually well tolerated. Patients with a VAD require systemic anticoagulation and antiplatelet therapy, which could potentially decrease the risk of paradoxical embolization in an MASVC. Taking down a Fontan circulation is a major surgical undertaking which would involve reoperative dissection, cardiopulmonary bypass, and surgical reconstruction in a patient with marginal end organ function and deranged coagulation. By relieving the venous congestion and improving end organ perfusion, the MASVC should be able to provide a more favorable physiology for postoperative recovery. Taking down a lateral tunnel Fontan or an intra-/extracardiac Fontan should be less challenging. The takedown of an extracardiac Fontan can be simplified by anastomosing the extracardiac conduit to the common atrium and avoiding the need for an inferior vena cava to atrium anastomosis.
There are several limitations to our study. Although the animal model used in this study effectively replicates a single ventricle parallel circulation, it is not a heart failure model and doesn't accurately represent the takedown of a failed Fontan circulation. Simulating a Fontan takedown is challenging due to the lack of a reliable chronic Fontan animal models. After the MASVC was established, the ventricular contribution to the cardiac output could not be measured, as there was not enough ascending aorta available for placement of a flow probe. The measured Qs slightly underestimated the cardiac output. Although a hemodynamically stable MASVC was established, the serum lactate in all animals didn't normalize to pre-bypass baseline level after two hours of support. A rise in serum lactate was observed immediately after weaning from CPB and in three of the four animals demonstrated a decreasing trend after two hours of support. One animal had an elevated serum lactate at baseline which peaked on weaning from bypass and remained elevated. The rise in lactate could be attributed to cardiopulmonary bypass and acute transitioning of an acyanotic biventricular circulation to a mixed single ventricle circulation. A longer period of support is probably required to normalize the serum lactate to prebypass levels. Although the cardiac output in the MASVC was comparable to baseline cardiac output, it is possible that it was inadequate to support the acute postoperative state in animals previously not exposed to cyanosis, leading to elevated serum lactate levels. Future studies could include higher pump rpm to increase systemic flow with longer duration of support to determine whether the lactate levels normalize. Due to the short duration of support, adequacy of oxygen delivery and long-term sustainability of MASVC could not be assessed. In a mixed parallel circulation, a higher HCT of about 40% is recommended to optimize the oxygen carrying capacity. In this study, the mean HCT achieved with a Qp/Qs ratio of 1:1 was 29.9%; despite the low HCT, the mean MVO 2 was greater than 50%. In comparison with the Qp/Qs ratio of 1.5:1, the mean MVO 2 dropped to about 50% with an increase in oxygen extraction. The decrease in mixed venous saturation could be explained by the lower mean HCT observed at the end of two hours of support. Hemodilution and surgical bleeding probably contributed to the decrease in HCT. More extensive statistical analysis of the lactate and MVO 2 trends and correlation with Qp/Qs was not possible due to the small sample size of n ¼ 4. Despite these limitations, we believe this preliminary study provides valuable data and would serve as a launching point for further research in single ventricle mechanical circulatory support.
An MASVC can achieve the twin objectives of augmenting cardiac output along with complete decompression of the venous system. It can be used to treat all three mechanisms of Fontan failure and can be implemented using a commercially available VAD. In this initial study, we demonstrated that an MASVC can be established in a porcine single ventricle model. We believe an MASVC could potentially be an effective strategy for mechanically supporting a single ventricle circulation. Future prolonged support studies with longer duration under anesthesia and studies of chronic awake animal are needed to determine long-term durability and end organ function using this strategy.
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